{"id":44891,"date":"2023-01-19T14:40:00","date_gmt":"2023-01-19T13:40:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/torbjorn-skold-appointed-new-ceo-of-stille-ab\/"},"modified":"2024-02-23T11:53:48","modified_gmt":"2024-02-23T10:53:48","slug":"torbjorn-skold-appointed-new-ceo-of-stille-ab","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/torbjorn-skold-appointed-new-ceo-of-stille-ab\/","title":{"rendered":"Torbj\u00f6rn Sk\u00f6ld Appointed New CEO of Stille AB"},"content":{"rendered":"
Stille AB (publ) announces the board of director\u2019s decision to appoint Torbj\u00f6rn Sk\u00f6ld as the new CEO of Stille AB. Torbj\u00f6rn Sk\u00f6ld has long experience from leading positions where the last 20 years have been within Life science with a primary focus on orthopedics and neurosurgery. The board of directors sees Torbj\u00f6rns background and experience as great value, and he is well-suited to further enhance Stille\u2019s strategy and increase shareholder value.<\/strong><\/div>\n

Torbj\u00f6rn will begin his tenure on March 20th, 2023, where he will replace Hanna Ernestam Wilkman who has been the company\u2019s CEO since April 1st, 2019. Torbj\u00f6rn comes most recently from De Puy Synthes EMEA, a Johnson & Johnson company, where he has been Vice President.<\/span><\/p>\n

Lars Kvarnhem, chairman of the board comments today\u2019s announcement: \u201cFirst, I would like to thank Hanna Ernestam Wilkman for her contributions to the company. Hanna has formed a professional organization and managed to lead the company over the past years which have been particularly challenging considering the COVID-19 pandemic. I am very happy to have been able to recruit Torbj\u00f6rn to become Stille\u2019s new CEO. Torbj\u00f6rn has a long experience of leading MedTech companies and has substantial experience in international sales and leadership, which suits Stille well.\u201d<\/em><\/span><\/p>\n

Torbj\u00f6rn Sk\u00f6ld comments the appointment: \u201cI really look forward to becoming the CEO of Stille. The company has an exciting future ahead with great growth potential within both its business units. The company has a strong brand, premium products, and a clear strategy.\u201d<\/em><\/span><\/p>\n

Torsh\u00e4lla, January 19th, 2023.<\/span><\/p>\n

<\/p>\n

This information is such information that Stille AB is obliged to disclose according to the EU\u2019s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on January 19th, 2023, kl. 14.40 (CET).<\/em><\/p>\n

\n

For more information, please contact:<\/span><\/span><\/p>\n

Lars Kvarnhem<\/span><\/span><\/strong>
\nChairman of the Board
\n+46 (0)70 512 00 21 | lars.kvarnhem@priego.se\u00a0<\/span><\/span><\/p>\n<\/div>\n

\n

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.<\/span><\/span><\/p>\n<\/div>\n